Company intelligence / Profile preview
Protagonist Therapeutics, Inc.
Newark, California, United States of Americaprotagonist-inc.com ↗
- Ownership
- Public · PTGX
- Employees
- ~126
- Development stage
- Phase 3
01
Overview
Protagonist has two lead candidates in Phase 3 clinical trials: Rusfertide for polycythemia vera (met primary endpoint in VERIFY trial) and Icotrokinra (JNJ-2113) for plaque psoriasis. Both are expected to file NDAs with the FDA in 2025. The company also has several earlier-stage programs in development.
- Therapeutic areas
- GastroenterologyRheumatologyEndocrinologyDermatologyHematology
- Modalities
- Peptide-based therapeuticsPeptide mimeticsOral peptides
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Takeda PharmaceuticalsJanssen Biotech (Johnson & Johnson)
04
Financials
- Market cap
- $8.8B
- Total revenue
- $46M
- Enterprise value
- $7.9B
Beyond the preview
Go deeper on Protagonist Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protagonist Therapeutics, Inc..